Cardio3 Biosciences is set to become the latest European biotech to pitch up on Wall Street in search of cash from public investors. And with a clinical-phase CAR-T asset in its pipeline, the Belgian biotech stands a chance of tapping into investor enthusiasm for the red-hot niche.
PledPharma has posted Phase IIb data linking its oxidative stress protector to a 43% drop in incidence of chemotherapy-induced peripheral neuropathy. The data triggered a 20% jump in the stock price of the company as investors responded to the results and talk of a possible partnership.
The quick-fire pace of biotech IPOs in Paris is set to continue. Inner ear disease specialist Sensorion is the latest to set terms for an IPO that will see it join Cerenis Therapeutics, Ose Pharma and Poxel in a Parisian class of 2015 that has already almost swelled to the size of last year's crop.
The European Directorate for the Quality of Medicines has banned products from a Chinese maker of iodine after an inspection at its plant by French inspectors turned up contamination issues in its manufacturing processes, issues with its purified water system and a piece of testing equipment that may have been put in the facility just for show.
In this week's EuroBiotech Report, Malin pulled in a blockbuster €330 million IPO, putting it among the biggest ever European biotech listings. Malin is targeting pre-IPO biotechs, a group that will find it easier to access public markets if a European equivalent of the JOBS Act, the U.S. legislative rethink that opened the current biotech IPO window, is passed. And more.
A consortium of financial trade groups has begun lobbying the European Commission to implement the sort of changes that triggered the U.S. biotech IPO boom. The European IPO Task Force specifically wants politicians to slash the regulatory and administrative cost of going public by up to 50%, a move that would make it financially feasible for more small companies to float.
Joint Polish Investment Fund Management is claiming a first. The Warsaw, Poland-based group has reportedly become the country's first institutional venture capital fund dedicated to life sciences after it held the initial closing of its $42 million (€38 million) investment vehicle.
Norwegian drugmaker Weifa figures its consumer health biz and its contract active pharmaceutical ingredient operations both have a better shot at growth if they go their separate ways. To make that happen, Weifa plans on spinning the API business off into a contract manufacturing operation, with its first contract to make the APIs for Weifa.
Shares in Silence Therapeutics jumped more than 20% on the back of Phase IIa data. The small trial was designed primarily to assess the safety and pharmacokinetics of the pancreatic cancer drug, but that did little to deter investors from latching on to some encouraging early efficacy data.
Seventure Partners has added €25 million ($27 million) to its microbiome investment fund, bringing the total under management to €100 million. The move ups the financial firepower of the fund--which has invested in 5 companies since it started late in 2013--at a time when microbiome R&D is starting to take off.